caa a22 4500 445807954 CHVBK 20180317145202.0 cr unu---uuuuu 170323e20110901xx s 000 0 eng 10.1007/s00415-011-5975-3 doi (NATIONALLICENCE)springer-10.1007/s00415-011-5975-3 Effects of acute relapses on neuropsychological status in multiple sclerosis patients [Elektronische Daten] [S. Morrow, S. Jurgensen, F. Forrestal, Frederick Munchauer, R. Benedict] Little is known about neuropsychological status changes in multiple sclerosis (MS) patients experiencing a relapse. The Symbol Digit Modalities Test (SDMT) and MS Neuropsychological Screening Questionnaire (MSNQ) are brief measures of cognitive performance and self-reported status, respectively. We retrospectively identified relapses in subjects participating in the 48-week open-label, safety-extension study of natalizumab (STRATA) to determine if changes in cognitive ability occurred during acute relapses. SDMT and MSNQ were administered prior to infusions. We analyzed SDMT and MSNQ scores pre- and post-relapse in 53 MS patients with relapses (cases) and 115 MS patients without relapses (controls) matched on age, gender, baseline SDMT and time from study initiation. ANOVA and GLM were used to compare cases versus controls overall, and stratified by EDSS cerebral functional status (cFS) scores. SDMT change pre- to post-relapse in cases was significantly lower than difference between similar time points in controls (p=0.003). When comparing visit 2 (two visits pre-relapse) to visit 1 (first visit post-relapse), MSNQ change was significantly different between cases and controls (p=0.012). For cFS≤1, the change in SDMT was significantly different between cases and controls but not for cFS≥2. These results confirm the involvement of cognitive function during some MS relapses suggesting the SDMT or MSNQ can be used to identify transitory neuropsychological status changes and cognitive relapses. Springer-Verlag, 2011 Multiple sclerosis nationallicence Relapse nationallicence Cognition nationallicence Morrow S. Jacobs Neurological Institute, State University of New York at Buffalo, Buffalo, NY, USA aut Jurgensen S. Biogen Idec, Inc., Cambridge, MA, USA aut Forrestal F. Biogen Idec, Inc., Cambridge, MA, USA aut Munchauer Frederick Biogen Idec, Inc., Cambridge, MA, USA aut Benedict R. Jacobs Neurological Institute, State University of New York at Buffalo, Buffalo, NY, USA aut Journal of Neurology Springer-Verlag 258/9(2011-09-01), 1603-1608 0340-5354 258:9<1603 2011 258 415 https://doi.org/10.1007/s00415-011-5975-3 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00415-011-5975-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Morrow S. Jacobs Neurological Institute, State University of New York at Buffalo, Buffalo, NY, USA aut NATIONALLICENCE 700 1- Jurgensen S. Biogen Idec, Inc., Cambridge, MA, USA aut NATIONALLICENCE 700 1- Forrestal F. Biogen Idec, Inc., Cambridge, MA, USA aut NATIONALLICENCE 700 1- Munchauer Frederick Biogen Idec, Inc., Cambridge, MA, USA aut NATIONALLICENCE 700 1- Benedict R. Jacobs Neurological Institute, State University of New York at Buffalo, Buffalo, NY, USA aut NATIONALLICENCE 773 0- Journal of Neurology Springer-Verlag 258/9(2011-09-01), 1603-1608 0340-5354 258:9<1603 2011 258 415 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer